Elena Nikulina

Regeneron Pharmaceuticals partners with Tessera Tx on genetic breakthrough

Regeneron Pharmaceuticals partners with Tessera Tx on genetic breakthrough
@Regeneron: Genetic breakthrough partnership

Regeneron Pharmaceuticals has announced a significant collaboration with Tessera Therapeutics, aiming to revolutionize genomic medicine.

The partnership will integrate Regeneron's expertise in genetics and genetic medicines with Tessera's innovative Gene Writing™ genome engineering technology.

The collaboration between Regeneron and Tessera builds on a foundation of innovation seen in Regeneron's prior advancements. The company's commitment to advancing heart health was underscored by the release of pivotal Phase 2 data in The Lancet, highlighting progress in cardiovascular research. Meanwhile, groundbreaking developments in hematology were evident when Regeneron unveiled new blood cancer data at ASH25, signaling a broader strategy in genetic and genomic medicine.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.